XTX Topco Ltd Sells 36,990 Shares of IceCure Medical Ltd. (NASDAQ:ICCM)

XTX Topco Ltd decreased its holdings in IceCure Medical Ltd. (NASDAQ:ICCM) by 62.8% during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 21,876 shares of the company’s stock after selling 36,990 shares during the quarter. XTX Topco Ltd’s holdings in IceCure Medical were worth $26,000 at the end of the most recent quarter.

Separately, Geode Capital Management LLC boosted its stake in IceCure Medical by 58.3% during the 4th quarter. Geode Capital Management LLC now owns 40,453 shares of the company’s stock valued at $44,000 after purchasing an additional 14,893 shares during the last quarter. 0.62% of the stock is owned by institutional investors.

IceCure Medical Trading Up 6.7%

Shares of ICCM stock opened at $0.90 on Friday. IceCure Medical Ltd. has a 52-week low of $0.48 and a 52-week high of $1.66. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.48 and a current ratio of 1.18. The company has a 50-day simple moving average of $0.98 and a two-hundred day simple moving average of $1.13. The company has a market capitalization of $52.73 million, a price-to-earnings ratio of -5.61 and a beta of 0.32.

IceCure Medical (NASDAQ:ICCM) last issued its quarterly earnings data on Wednesday, August 13th. The company reported $0.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.12. IceCure Medical had a negative net margin of 317.62% and a negative return on equity of 136.96%. The business had revenue of $0.66 million during the quarter, compared to the consensus estimate of $0.90 million. Research analysts anticipate that IceCure Medical Ltd. will post -0.28 EPS for the current fiscal year.

Analysts Set New Price Targets

ICCM has been the subject of a number of analyst reports. Loop Capital set a $2.77 price target on IceCure Medical in a research note on Wednesday. HC Wainwright reiterated a “buy” rating and set a $2.00 price target (down previously from $2.50) on shares of IceCure Medical in a research note on Friday. Brookline Capital Management reiterated a “buy” rating on shares of IceCure Medical in a research note on Wednesday. Finally, Wall Street Zen downgraded IceCure Medical from a “hold” rating to a “sell” rating in a research note on Saturday, July 12th.

IceCure Medical Profile

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.